Clariness Announces Role in Supporting YPrime's Patient and Site eCOA Initiatives
Clariness tasked with gathering data on digital device usage behaviors, app and notification preferences, and previous trial experiences.
Clariness announces its support of YPrime’s ongoing commitment to enhance the patient and site eCOA experience, by delivering insights from more than 2,000 patients, in four countries, assessing patient demographics and psychographics.
Assessing the digital behaviors and trial awareness of a diverse international population, Clariness received patient insights across five therapeutic areas, including oncology, immunology, rare diseases, central nervous system, and dermatology.
Clariness was tasked with providing insights from 1,600 patients, gathering data on digital device usage behaviors, app and notification preferences, and previous trial experiences. Clariness delivered insights from over 2,000 patients, in two months, which could be segmented by patient age, medical condition, education level, ethnicity, spoken language, and more.
Reference
Clariness delivers more than 50,000 patient data points to drive YPrime’s customer experience. (2023, April 24). Clariness.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025